Protein inhibitors provide a physiological mechanism of regulation of proteolytic enzymes. While most single-domain inhibitors have one reactive site with which they target peptidases of a specific catalytic class, selected specimens inhibit two peptidase molecules simultaneously, thus giving rise to ternary complexes. To study such inhibition, we analyzed the function of one of these proteins, sermetstatin, which strongly binds as a dimer to serine proteinases (SPs) and a metallopeptidase (MP). In addition, we 10 determined the structures of the isolated inhibitor dimer and its heterotetrameric complexes with the SP subtilisin and the MP snapalysin, which reveal that inhibition occurs through two independent distal reactive sites. These structures and the derived model for the heterohexameric complex provide for the first time a detailed view of the molecular mechanism of simultaneous inhibition of proteinases belonging to two distinct mechanistic classes by a single-domain protein.
Introduction
Due to the essentially irreversible nature of peptide-bond hydrolysis, proteolytic enzymes must be tightly regulated to prevent spatially and temporally deleterious activity. One such regulatory mechanism is provided by co-localizing protein 20 inhibitors which mostly target one or several peptidases of a certain catalytic class through a single inhibitory region by blocking the active-site cleft of the enzyme 1, 2 . A special case is provided by inhibitors with two inhibitory sites which mimic the head architecture of the Roman god Janus and are capable of 25 inhibiting two peptidase molecules simultaneously 3 . Such Janusfaced inhibitors (see Suppl. Table S1 ) are infrequent among the plethora of inhibitors described, and none of them has yet been structurally characterized in a ternary complex with two different targets. 30 To address this question, we focused on the bacterial genus Streptomyces, which occurs in soil and aquatic habitats and is the source of many medicinal, pharmaceutical, and industrial products of natural origin such as antibiotics 4 . These bacteria secrete a number of peptidases and cognate protein inhibitors 35 thought to participate in morphological development and defense against extrinsic proteinases. Among these inhibitors are members of family I16 (according to MEROPS inhibitor database, http://merops.sanger.ac.uk; 5 ), which only occur within the bacterial order Actinomycetales. These inhibitors generally 40 target serine proteinases (SPs) of the chymotrypsin-and subtilisin-type; some also bind tightly to Streptomyces griseus griselysin but apparently not the structural and functional relative thermolysin from Bacillus thermoproteolyticus, which is in MEROPS metallopeptidase (MP) family M4 5 . This inhibition is 45 exerted by the same region employed for SPs 6 , so that, although they are bi-functional, dual inhibition cannot occur simultaneously. Previously studied I16 inhibitors include Streptomyces subtilisin inhibitor (SSI) from Streptomyces albogriseolus, plasminostreptin from Streptomyces 50 antifibrinolyticus, alkaline protease inhibitor API-2c' from Streptomyces pseudogriseolus, and trypsin inhibitor STI2 from Streptomyces longisporus 5, 7-11 (see Fig. 1a ). Among them is also sermetstatin-also known as Streptomyces caespitosus neutral proteinase inhibitor 8 -, which is a 113-residue secreted single-55 domain molecule and the main object of study of the present work.
Inhibitory profile of sermetstatin
We produced sermetstatin by recombinant overexpression in Escherichia coli (see Experimental procedures in the Electronic
60
Supplementary Information [ESI] ) and found it to be a homodimer in solution, thus confirming earlier results 8 . We assessed its inhibitory function, which had been previously ruled out for the cysteine proteinase cathepsin B and the aspartic proteinase pepsin 8 , against a broad panel of model peptidases F60 and G212-F213 (S. coelicolor prosnapalysin numbering in regular characters; see UniProt sequence database access code P0A3Z7), which removed not only the N-terminal part but also a 15-residue C-terminal fragment, as previously described for the MP ulilysin from Methanosarcina acetivorans 15 . Subsequently, 10 several cleavages occurred in the remaining part of the 49-residue propeptide to finally yield the mature 133-residue form spanning residues A80-G212. Consistent with an autolytic mechanism in vitro, mutant E164A, which affects the glutamate that plays the role of a general base/acid in the catalytic process in MPs 12, 16, 17 , 15 displays only very slow activation over a period of weeks. In nature, however, prosnapalysin activation is likely to occur under assistance of other proteinases. Further to snapalysin, sermetstatin did not inhibit any other MP assayed, which included thermolysin and metzincins of the 20 astacin, pappalysin, serralysin, fragilysin, ADAM/adamalysin and matrix metalloproteinase families. Taken together with previous results showing no inhibition of the M4-family MPs Pseudomonas aeruginosa elastase and vimelysin, as well as the unassigned MP almelysin 8 , we conclude that sermetstatin is most 25 likely a specific inhibitor of snapalysins through one of its Janus faces. In addition, sermetstatin potently inhibited subtilisin Carlsberg from Bacillus licheniformis (with an apparent K i of 1.3nM) and proteinase K (Suppl. . Table S2 ). These results confirm that sermetstatin is a potent, though rather broadspectrum inhibitor of subtilisin-type-and, 35 partially, chymotrypsin-type-SPs through its other Janus face.
Structure of sermetstatin
We crystallized and solved the structure of sermetstatin by single-wavelength anomalous 40 diffraction with the help of a selenomethione derivative (see ESI and Suppl. Table S3 ). The protein is an elongated α/β-sandwich of maximal dimensions 45x30x25Å. It consists of a fivestranded antiparallel β-sheet (β3-β2-β1-β4−β5; 45 connectivity -1,-1,+3,+1) twisted by ~30º, whose concave face accommodates two α-helices (α1 and α2) and a 3 10 -helix (η1; see Figs. 1a and 2a). The overall structure is tethered by a large hydrophobic core provided by side chains of the 50 β-sheet on its concave face, the two α-helices, and the C-terminal tail. The structure is further maintained by two disulfide bonds. The first (C 31 -C 46 ; sermetstatin mature-protein residues numbered in superscript; see Fig. 1a and subtract 55 28 from UniProt Q9FDS0 numbers) links the first "scaffold helix" α1 with β2 and the subsequent loop connecting strands β2 with β3 (Lβ2β3), which includes the "reactive-site loop 1" (C 31 -A 35 ). The second disulfide bond (C 69 -C 99 ) 60 connects the second "scaffold helix" α2 with Lα2β4, which contains the "reactive-site loop 2" (P 65 -F 73 ). Both reactive-site loops protrude from the molecular surface and are fully solvent accessible (Fig. 2a) . The C-terminal carboxylate is anchored to the side chain of R 25 within β2; by contrast, the N-65 terminus loosely protrudes from the molecular surface and becomes only rigid at P 5 , which leads to the first residue of strand β1.
Two sermetstatin molecules intimately associate through the convex faces of their β-sheets to yield a crystallographically-70 related dimer (Fig. 2a) , in agreement with the oligomeric state found in solution. The sheet planes are rotated by ~35º away from each other and the interaction surface spans ~800Å 2 , viz. 25% of the total surface of a monomer. The interaction is mainly hydrophobic and made by 31 close contacts, which include 75 symmetric hydrophobic interactions between ten residues provided by each sheet of either monomer, and only two salt bridges between R 88 of one protein chain and D 81 of the other. Structure similarity searches with sermetstatin against the Protein Data Bank (PDB) only identified the I16-family relative
Structure of the subtilisin: sermetstatin complex
The crystal structure of the complex between subtilisin Carlsberg and sermetstatin was determined by Patterson search and reveals a 2+2 heterotetramer as 5 anticipated by studies in solution, with a central non-cleaved inhibitor dimer-as present in the unbound structure-and one enzyme moiety bound to each inhibitor monomer ( Fig. 2b and Suppl. active-site cleft of the enzyme (Fig. 3a) . The loop, which includes the reactive-site bond M 71 -Y 72 , is inserted wedge-like mimicking a substrate in extended, "canonical" conformation in the active-site 25 cleft of the enzyme following the "standard mechanism" of inhibition, terms which were coined by Laskowski, Bode, Huber, and others 1, 2, 22 . This mechanism has only been structurally proven to date for SP 30 inhibitors in general and for the specific insect metalloproteinase inhibitor of thermolysin-family MPs 23 . Rigidity to reactive-site loop 2 is conferred by the proline at position P2 (active-site cleft and 35 substrate sub-site nomenclature according to 17, 24 (Fig. 3a) . The small interacting surface between enzyme and inhibitor-despite high inhibitory 65 potency (see above)-means that upon superposition of the proteinase moieties of the two complexes within the heterotetramer, the inhibitor moieties display a relative rotation of ~10º around an axis horizontally traversing the active-site cleft
This journal is © The Royal Society of Chemistry [year] ( Fig. 3b) . In addition, it also explains why several SPs are targeted by the inhibitor, as no exosites are employed for binding that could confer specificity. Finally, superposition of the complex with the one reported between SSI and subtilisin BPN' 5 (PDB 2SIC; 19 ) reveals very similar binding. As observed in the asymmetric unit of the subtilisin:sermetstatin structure, a relative reorientation between the sermetstatin and SSI inhibitor moieties-here of ~20º-is found upon superposition of the respective enzyme parts (Fig. 3c ).
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Redesign of inhibitory specificity
Inhibitory studies with wild-type sermetstatin revealed only weak activity against trypsin (Suppl . Table S2 and  8 ) , possibly owing to the presence of a methionine in P1 (M 71 ). In order to design a better inhibitor of the latter SP, we produced a mutant, 15 
M
71 K, to match the specificity of trypsin. While this mutant did not have any influence on the MPs tested, it showed a twofold increase in trypsin inhibition and a substantial decrease in the inhibition of hydrophobic S1-specific SPs of subtilisin type (subtilisin Carlsberg and proteinase K) and chymotrypsin type 20 (chymotrypsin and elastase), i.e. we were able to alter the specificity of sermetstatin. In addition, we also replaced positions P1' and P2' of sermetstatin with the residues found in SSI (mutant Y 72 V+F 73 Y; see Fig. 1a ) to assess the importance of these sites but could not observe any significant inhibitory 25 difference with the wild-type (Suppl. Table S2 ).
Structure of the snapalysin: sermetstatin complex
The crystal structure of the complex between S. caespitosus snapalysin and sermetstatin was determined by multi-step Patterson search and also shows a heterotetrameric 2+2 30 quaternary structure (Fig. 2c and Suppl. 40 minor structural deviations from the unbound structure as seen in the subtilisin complex. However, unlike the unbound structure and the latter complex, reactive-site loop 2 is flexible 45 and partially disordered in some of the polypeptide chains. Snapalysin, in turn, is in a virtually identical conformation to the unbound structure (PDB 1KUH; 26 ) throughout its entire structure except 50 for loop A 36 -A 40 (italicized S. caespiosus snapalysin residues and subscript numbers according to the mature MP sequence; see UniProt P56406), which is distal from the 55 active-site cleft and thus the zone of interaction with sermetstatin. Within the complex, the proteinase is bound by a region on the opposite surface to the subtilisin binding site ( , and G 105 -P 108 of the proteinase moiety. This implies that not only the active-site cleft is targeted during inhibition but also exosites on the protease surface, and this, in turn, explains the specificity of this second Janus face for snapalysin. 75 The present inhibition modus follows a novel mechanism for MP inhibitors: the N-terminal segment is inserted in a substratelike manner in canonical conformation into the non-primed side of the active-site cleft, thus establishing a β-ribbon-type interaction with the β-strand above the active-site cleft at A 55 -D 58 80 (see Fig. 4 ). The side chain of H 3 is directed toward the peptidase moiety and approaches the zinc-bound catalytic solvent through a solvent bridge. To assess this interaction, we constructed two point mutants, H 3 R and H 3 E, which showed inhibitory activity indistinguishable from that of the wild type (data not shown), 85 which is logical as the structure should be able to accommodate both changes simply through removal of the bridging solvent. The second main interacting region for inhibition between snapalysin and sermetstatin is provided by reactive-site loop 1, which penetrates cleft sub-site S1' with Y 33 , thus matching the 90 substrate specificity of the MP 26, 27 (Fig. 4) . The aromatic side chain approaches R 79 , which creates the bottom of the hydrophobic S1' pocket of the enzyme through the aliphatic part of its side chain. Due to the intrusion of reactive-site loop 1, Y 95 , which is in a position indistinguishable from that seen in the 95 unbound structure 26 and is generally supposed to stabilize the (Fig. 1a) , and found only residual inhibitory 5 activity against snapalysin, while the behavior against SPs was unaltered (Suppl. Table S2 ). This supports an authentic key role in inhibition for this second Janus-face site, which is absent in SSI and, most likely, other I16 inhibitors studied, which are evolutionarily more distant from sermetstatin than from each 10 other (Fig. 1a) . In addition, secondary snapalysin:sermetstatin interaction sites are provided by sermetstatin helix α1, which interacts with the segment immediately downstream of the third zinc-binding residue of snapalysin (D 93 -G 97 ), and Lβ4β5, which contacts the upper-rim strand of the peptidase on its non-primed 15 side (Fig. 4) . In particular, D 47 of α1 approaches the main-chain amide nitrogen atoms of both Y 95 and Q 96 through its side chain. This causes the side chain of the latter residue to be pulled out towards bulk solvent in the complex. Finally, the frontal bulge segment above the primed-side of the active-site cleft of 20 snapalysin, R 51 -D 58 , interacts with three short segments of the second sermetstatin molecule (chain D) within the heterotetramer at V 23 -T 28 , G 37 -P 40 , and F 113 through four hydrogen bonds. Overall, this type of enzyme:inhibitor interaction is only distantly reminiscent of the inhibitory mode of tissue inhibitors of 25 metalloproteinases on their target matrix metalloproteinases 28 and of serralysin inhibitors on their cognate serralysin MPs 29 . In these cases, N-terminal tails likewise bind in extended conformation but are found in the primed side of the cleft. 30 Disulfide bonds are a common feature of proteinase inhibitors that follow the standard mechanism, and we set out to assess the importance of the two that link the reactive-site loops to their subjacent scaffold helices by mutating the cysteine residues to serine. Wild-type sermetstatin, as well as mutants C 31 40 inhibitor still had sufficient structural integrity to maintain its MP site functional but not to prevent the SP site from collapsing. By contrast, mutant C 31 S+C 46 S, which was obtained with a much lower yield than the wild-type, was readily degraded by both peptidases, strongly suggesting that this 45 disulfide is essential for the overall structural conformation of the inhibitor. Accordingly, the disulfide bonds of sermetstatin are required for its double inhibitory activity because they reduce the 50 conformational flexibility of the main chain around the reactive site and contribute to maintaining the overall scaffold in a competent conformation.
Disulfide bonds in sermetstatin
Model for the ternary complex
55
All the structural information described has allowed us to construct a composite model of the ternary complex between subtilisin, sermetstatin, and snapalysin (Fig. 2d) . This model shows a large 60 inhibitory particle of maximal dimensions 120x85x65Å, which is rather asymmetric and resembles a distorted cross with a large vertical bar arched by ~55º and a short horizontal bar, which intersect at an angle of ~75º. The model confirms the heterohexameric 2+2+2 arrangement found in 65 solution (see ESI and Suppl. Fig. S1 ); no steric hindrance is observed upon peptidase binding to the distal inhibitory sites, and the proteinase surfaces are at least ~15Å apart.
In summary, sermetstatin is a genuine Janus-faced dimeric single-domain inhibitor which has evolved from single-site 70 standard-mechanism SP inhibitors of family I16 to give a protein capable of simultaneous inhibition of SPs in general and a specific MP through distinct but compatible sites. Tables  11  Supplemental Table S1 11 Supplemental Table S2  12  Supplemental Table S3  13 Production and purification of snapalysin -A synthetic gene coding for mature snapalysin from S. caespitosus, in which the N-terminal threonine had been replaced by methionine due to the cloning strategy, was purchased (GenScript) and cloned into a modified pET-28a vector between the NcoI and XhoI restriction sites. This vector attaches an N-terminal His 6 fusion tag, followed by a TEV protease recognition site. The protein was overproduced as inclusion bodies in E. coli BL21 (DE3) cells, which were grown at 37°C in LB medium supplemented with 30µg/ml kanamycin, induced at an OD 550 of 0.8 with 1mM IPTG, and grown for a further 5h at 37°C. After centrifugation at 7,000xg for 30min at 4°C, the pellet was resuspended in buffer D (PBS, 1% Triton X-100, pH7.4) containing EDTA-free protease inhibitor cocktail tablets and DNase I. Cells were lysed at 4ºC using a cell disrupter at a pressure of 1.9Kbar and incubated for 30min at 37°C. The inclusion bodies were recovered by centrifugation at 7,000xg for 30min at 4°C and washed twice with buffer D, resuspended in buffer A, 8M urea, and incubated for 5h at room temperature under vigorous shaking. The sample was centrifuged at 50,000xg for 1h at 20°C, the supernatant was incubated with Ni-NTA resin previously equilibrated with buffer A, 8M urea, and the fusion protein was eluted using buffer E (50mM sodium phosphate, 250mM NaCl, 8M urea, pH4.0). The sample was dialyzed overnight at room temperature against buffer A plus 0.5mM GSSG, 1mM GSH, 10mM CaCl 2 , 1mM ZnS0 4 , and 0.4M L-arginine, and subsequently dialyzed overnight at 4°C against buffer C. The N-terminal extension of the snapalysin construct was removed by autolytic cleavage as determined by Edman degradation, yielding an N-terminal segment Q -3 +G -2 +P -1 +M 1 (italicized snapalysin amino acids subscripted numbering correspond to UniProt P56406 plus the additional N-terminal tag residues and the T 1 M mutation; although this is a secreted protein, the signal-peptide sequence is unknown and the database entry corresponds to the authentic protein purified from culture supernatants of S.
Notes and references
caespitosus). The protein was concentrated by ultrafiltration, and further purified by size-exclusion chromatography on a Superdex 75 10/300 column previously equilibrated with buffer C. Protein identity and purity were assessed by Edman degradation and 15% Tricine-SDS-PAGE stained with Coomassie blue. Ultrafiltration steps were performed with Vivaspin 15 and Vivaspin 500 filter devices with 5-KDa cut-off. Protein concentration was determined by measuring the absorbance at 280nm using a NanoDrop spectrophotometer and a calculated absorption coefficient Ε 0.1% = 1.7. This procedure yielded functional snapalysin at very low concentration (approx. 50µg per liter of cell culture), which was used for activity assays (see below).
In vitro activation studies of prosnapalysin -To study the transition between latent and mature snapalysins, a synthetic gene encompassing the chemical sequence of prosnapalysin from
Streptomyces coelicor-the sequence of the pro-peptide of the zymogen from S. caespitosus is not known-lacking the 29-residue signal peptide and with the N-terminal alanine replaced with methionine (A30M; numbering in regular characters according to UniProt P0A3Z7) due to the cloning strategy, was purchased (GenScript) and cloned into the aforementioned modified pET-28a vector using the NcoI and XhoI restriction sites. Prosnapalysin active-site mutant E164A was obtained using the QuickChange Site-Directed Mutagenesis kit and verified by DNA sequencing. Both proteins were overproduced in E. coli BL21 (DE3) cells, which were grown at 37°C in LB medium supplemented with kanamycin to a final concentration of 30µg/ml. Thereafter, cells were induced at an OD 550 of 0.8 with IPTG to a final concentration of 1mM and grown for a further 5h at 37°C. After centrifugation at 7,000xg for 30min at 4°C, the pellet was resuspended in buffer D containing EDTA-free protease inhibitor cocktail tablets and DNase I. Cells were lysed at 4ºC using a cell disrupter at a pressure of 1.9
Kbar and incubated for 30min at 37°C. The resulting inclusion bodies were recovered by centrifugation at 7,000xg for 30min at 4°C and washed twice with buffer D, resuspended in buffer A, 8M urea, and incubated for 5h at room temperature under vigorous shaking. The sample was centrifuged at 50,000xg for 1h at 20°C, the supernatant was incubated with Ni-NTA resin previously equilibrated with buffer A, 8M urea, and the fusion protein was eluted using buffer E. The sample was then first dialyzed overnight at room temperature against buffer A plus 0.5mM GSSG, 1mM GSH, nm using a NanoDrop and a calculated absorption coefficient Ε 0.1% = 1.38 for both variants.
Proteolytic and inhibition assays -Ulilysin from Methanosarcina acetivorans, aeruginolysin
from Pseudomonas aeruginosa, and fragilysin-3 from Bacteroides fragilis were produced and purified as previously described [2] [3] [4] [5] . The vector coding for aeruginolysin was a kind gift from Ulrich Baumann / λ em = 528nm. Increasing amounts of purified wild-type and mutant variants of sermetstatin were added to the assays to determine inhibition (see Suppl. Table S2 ). In addition, inhibition of wild-type sermetstatin against subtilisin and snapalysin was tested by using the substrates succinyl-A-A-P-F-p- Cleavage of sermetstatin mutants -Wild-type sermetstatin, as well as mutants C 31 S+C 46 S and C 69 S+C 99 S (at 0.5mg/ml in 20mM Tris-HCl, 50mM NaCl, pH7.4), were incubated with equimolar amounts of either subtilisin or snapalysin overnight at room temperature. The reactions were then assessed for cleavage in a Bruker Autoflex III mass spectrometer. Each sample was mixed at a 1:1 ratio (v/v) with a matrix solution of sinapinic acid (10mg/ml, Sigma) dissolved in 30% acetonitrile and 0.1% trifluoroacetic acid, and subsequently spotted onto the plate using the dried-droplet method.
Mass spectra were acquired in linear mode geometry with >1,000 laser shots and using a protein mixture ranging from 5 KDa to 17.5 KDa (Protein Calibration Standard I, Bruker) as a calibrator.
Complex formation and purification -Commercial subtilisin Carlsberg from B. licheniformis
was purified by size-exclusion chromatography on a HiLoad 16/60 Superdex 75 column previously equilibrated with buffer C. The subtilisin:sermetstatin complex was formed by incubation of equimolar amounts of purified wild-type inhibitor and protease, and it eluted as a 2+2 heterotetramer in calibrated size-exclusion chromatography. The complex was concentrated by ultrafiltration up to 5.5mg/ml using Vivaspin 15 and Vivaspin 500 filter devices of 30-KDa cut-off. Protein concentration was determined by measuring the absorbance at 280nm using a NanoDrop spectrophotometer and a calculated absorption coefficient Ε 0.1% = 0.89. To produce sufficient amounts of snapalysin for structural studies, inclusion bodies of snapalysin were obtained and purified as described above. Next, unfolded snapalysin dissolved in buffer E was diluted 1:9 against buffer A, 0.55mM GSSG, 1.1mM GSH, 11mM CaCl 2 , 1.1mM ZnS0 4 , 0.44M L-arginine and an equimolar amount of wild-type sermetstatin. The sample was incubated for 4h at 4°C and dialyzed overnight at 4°C against buffer C.
The snapalysin:sermetstatin complex was concentrated by ultrafiltration, and further purified by sizeexclusion chromatography on a HiLoad 16/60 Superdex 75 column previously equilibrated with buffer C and calibrated, which revealed that the complex was a 2+2 heterotetramer in solution. The sample was dialyzed overnight at 4°C against buffer F (20mM Tris-HCl, 1M NaCl, pH7.4) and concentrated by ultrafiltration to 4.5mg/ml using Vivaspin 15 and Vivaspin 500 filter devices of 10-KDa cut-off.
The protein concentration was determined by measuring the absorbance at 280nm using a NanoDrop spectrophotometer and a calculated absorption coefficient Ε 0.1% = 1.32. Finally, the ternary complex between subtilisin, sermetstatin, and snapalysin was obtained by adding an equimolar amount of subtilisin to the snapalysin:sermetstatin complex. A further size-exclusion chromatography step in a calibrated Superdex 200 10/300 column previously equilibrated with buffer C revealed that the quaternary arrangement in solution was a 2+2+2 heterohexamer (see Suppl. Fig. S4 ). The complex was concentrated by ultrafiltration to 7.5mg/ml with Vivaspin 15 and Vivaspin 500 filter devices of 10-KDa cut-off. Protein concentration was determined by measuring the absorbance at 280nm using a NanoDrop spectrophotometer and a calculated absorption coefficient Ε 0.1% = 1.1.
Crystallization and X-ray diffraction data collection -Crystallization assays of sermetstatin, its two binary complexes with snapalysin and subtilisin, and the ternary complex with both peptidases were carried out by the sitting-drop vapor diffusion method. Table S3 ).
Structure solution and refinement -All attempts to solve the structure of unbound sermetstatin Table S3 ).
The structure of the snapalysin:sermetstatin complex was likewise solved by Patterson search using the coordinates of S. caespitosus snapalysin (PDB 1KUH; 19 ) and sermetstatin. Due to the presence of 12 molecules in the asymmetric unit in total, searches had to be split into two steps: first, four copies of each protein were searched for independently, enabling us to identify two complexes showing the same relative arrangement between proteinase and inhibitor. In a second search, one such complex was used as a search model, which yielded six solutions arranged as three 2+2 Table   S3 ). Due to the distinct packing environments of the molecules within the crystal, chains E and K were overall less well-defined by electron density that the other ten chains; this is indicated by the significantly higher average thermal displacement parameters for their protein parts (76.0 and 90.3Å 2 , respectively) than the remaining molecules (44.8-64.5Å 2 ).
A composite model of the ternary 2+2+2 complex between subtilisin, sermetstatin, and snapalysin was obtained with TURBO-Frodo starting from the subtilisin:sermetstatin complex after superposition of the dimeric inhibitor moieties of the binary complexes. Only the N-terminal segment, Lβ2β3, and segment β1-Lβ1β2-β2 had to be slightly remodeled to match the conformation found in the snapalysin:sermetstatin complex. These segments were subjected to geometric refinement with TURBO-Frodo.
Miscellaneous -Figures
were prepared with programs TURBO-Frodo and CHIMERA 20 .
Interaction surfaces (taken as half of the surface area buried at a complex interface) and close contacts (<4Å) were determined with CNS 21 . Structure similarities were investigated with DALI 22 . Model validation was performed with MOLPROBITY 23 and the WHATCHECK routine of WHATIF 24 .
Sequence alignments and phylogenetic calculations were performed with MULTALIN 25 . The final coordinates of sermetstatin, the subtilisin:sermetstatin complex, and the snapalysin:sermetstatin complex have been deposited with the PDB at www.pdb.org (access codes 4HWX, 4HX2, and 4HX3).
The model of the ternary complex is available from the authors upon request.
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Supplemental Tables
Suppl . Table S1 . Janus-faced single-domain inhibitors with at least two reactive sites. Values as mean of three independent measurements, SD within ±5. a ADAM stands for a disintegrin and metalloprotease, MMP for matrix metalloproteinase. b NI, no inhibition at 4 µM inhibitor concentration in a cell-based assay.
Supplemental Figures
Suppl. Figure S1 -Size-exclusion chromatography of the ternary complex. (a) The complex between subtilisin, sermetstatin and snapalysin was loaded onto a Superdex 200 10/300 column. The complex eluted after 13.3ml, which corresponds to 102KDa and reveals the formation of a 2+2+2 heterohexamer in solution (theoretical mass 107.8KDa). The column was calibrated with the following protein standards: aldolase (158KDa; elution after 12.5ml), conalbumin (75KDa; 13.9ml), ovalbumin (43KDa; 14.8ml), and cytochrome C (12.4KDa; 17.8ml). The presence of the three molecules (subtilisin 27KDa, snapalysin 15KDa, and sermetstatin 12KDa) was further confirmed by SDS-PAGE (see inset) after trichloroacetic acid-precipitation of the collected sample. (b) The isolated inhibitor and the binary and ternary complexes were loaded onto a Superdex 75 10/300 column for comparison. The sermetstatin eluted after 12.2ml (1+1), the snapalysin:sermetstatin complex after 11.6ml (2+2), the subtilisin:sermetstatin complex after 10.0ml (2+2), and the ternary complex after 9.2ml (2+2+2).
